Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft

被引：0
|
作者：
Stavart, Louis [1 ,2 ]
Halfon, Matthieu [1 ,2 ]
Dewarrat, Natacha [3 ]
Rotman, Samuel [4 ]
Golshayan, Dela [1 ,2 ,5 ]
机构：
[1] Lausanne Univ Hosp CHUV, Transplantat Ctr, Lausanne, Switzerland
[2] Lausanne Univ Hosp CHUV, Transplantat Immunopathol Lab, Lausanne, Switzerland
[3] Lausanne Univ Hosp CHUV, Serv & Cent Lab Hematol, Lausanne, Switzerland
[4] Lausanne Univ Hosp CHUV, Inst Pathol, Lausanne, Switzerland
[5] Univ Lausanne UNIL, Fac Biol & Med, Lausanne, Switzerland
来源：
FRONTIERS IN MEDICINE | 2024年 / 11卷
关键词：
chronic lymphocytic leukemia; kidney transplantation; Bruton tyrosine kinase inhibitor; acute cellular rejection; case report; B-CELL LYMPHOCYTOSIS; TRANSPLANTATION; IBRUTINIB; LYMPHOMA; PATIENT; DONOR;
D O I：
10.3389/fmed.2024.1451264
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The burden of chronic lymphocytic leukemia (CLL) in the prognosis of solid organ transplant (SOT) recipients seems non-negligible. Whether transplanting a patient with previous CLL is safe or what is the optimal monitoring and treatment management after transplantation is still unclear and only based on few case series and reports. Therefore, we aimed to contribute to this understanding by reporting the first documented case of a clinically significant CLL with biopsy-proven infiltration of the kidney allograft and its successful management with a Bruton tyrosine kinase inhibitor (BTKi). We then reviewed the related literature, with a focus on CLL and kidney transplantation. Our main message is that BTKi may represent a safe and effective intervention to prevent the hazardous patient and graft outcomes of CLL in SOT patients.
引用
收藏
页数：7
相关论文
共 50 条
  • [41] Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation
    Kanagal-Shamanna, Rashmi
    Jain, Preetesh
    Patel, Keyur P.
    Routbort, Mark
    Bueso-Ramos, Carlos
    Alhalouli, Tahani
    Khoury, Joseph D.
    Luthra, Rajyalakshmi
    Ferrajoli, Alessandra
    Keating, Michael
    Jain, Nitin
    Burger, Jan
    Estrov, Zeev
    Wierda, William
    Kantarjian, Hagop M.
    Medeiros, L. Jeffrey
    CANCER, 2019, 125 (04) : 559 - 574
  • [42] The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
    Ponader, Sabine
    Chen, Shih-Shih
    Buggy, Joseph J.
    Balakrishnan, Kumudha
    Gandhi, Varsha
    Wierda, William G.
    Keating, Michael J.
    O'Brien, Susan
    Chiorazzi, Nicholas
    Burger, Jan A.
    BLOOD, 2012, 119 (05) : 1182 - 1189
  • [43] Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey
    Stephens, Deborah M.
    Stewart, Chris
    Avruch, Liza
    Coombs, Catherine C.
    Danilov, Alexey
    Hill, Brian T.
    Shadman, Mazyar
    Gerrie, Alina S.
    Jensen, Christopher E.
    Hoffmann, Marc
    Winter, Allison M.
    Ermann, Daniel A.
    Barr, Paul M.
    O'Brien, Susan M.
    Koffman, Brian
    Byrd, John C.
    BLOOD, 2024, 144 : 7743 - 7745
  • [44] Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
    Woyach, Jennifer A.
    Bojnik, Engin
    Ruppert, Amy S.
    Stefanovski, Matthew R.
    Goettl, Virginia M.
    Smucker, Kelly A.
    Smith, Lisa L.
    Dubovsky, Jason A.
    Towns, William H.
    MacMurray, Jessica
    Harrington, Bonnie K.
    Davis, Melanie E.
    Gobessi, Stefania
    Laurenti, Luca
    Chang, Betty Y.
    Buggy, Joseph J.
    Efremov, Dimitar G.
    Byrd, John C.
    Johnson, Amy J.
    BLOOD, 2014, 123 (08) : 1207 - 1213
  • [45] Tailoring Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    Mauro, Michael J.
    CANCER CONTROL, 2009, 16 (02) : 108 - 121
  • [46] Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects
    Mansour, Anthony G.
    Huang, Ying
    Alsouqi, Aseel
    Kittai, Adam S.
    Byrd, John C.
    Grever, Michael R.
    Miller, Cecelia
    Lozanski, Gerard
    Moran, Mollie
    Lucas, Margaret S.
    Suresh, Swetha
    Grantier, Cara
    Hoffman, Corinne
    Reid, Mark
    Rogers, Kerry A.
    Bhat, Seema A.
    Woyach, Jennifer A.
    BLOOD, 2024, 144 : 4629 - 4630
  • [47] Tolerability and Outcomes of Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia in Patients with Severe Renal Dysfunction
    Lin, Chenyu
    Anderson, Clare E.
    Scobie, Micaela R.
    Rodgers, Thomas D.
    Kelley, Michael J.
    Friedman, Daphne R.
    BLOOD, 2023, 142
  • [48] Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review
    Din, Mohammad Ammad Ud
    Liaqat, Hania
    Anwer, Faiz
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2022, 44 (02) : 293 - 296
  • [49] Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia
    Kil, Laurens P.
    de Bruijn, Marjolein J. W.
    van Hulst, Jennifer A. C.
    Langerak, Anton W.
    Yuvaraj, Saravanan
    Hendriks, Rudi W.
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2013, 3 (01): : 71 - 83
  • [50] Targeting Bruton's tyrosine kinase expression levels through microRNAs in chronic lymphocytic leukemia treatment
    Singh, Simar Pal
    Rip, Jasper
    Hendriks, Rudi W.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S502 - S507
12345